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Abstract
Background: Defective insulin secretion is a key defect in the pathogenesis of type 2 diabetes
(T2DM). The β-cell specific transcription factor, insulin promoter factor 1 gene (IPF1), is essential
to pancreatic development and the maintenance of β-cell mass. We hypothesized that regulatory
or coding variants in IPF1 contribute to defective insulin secretion and thus T2DM.
Methods: We screened 71 Caucasian and 69 African American individuals for genetic variants in
the promoter region, three highly conserved upstream regulatory sequences (PH1, PH2 and PH3),
the human β-cell specific enhancer, and the two exons with adjacent introns. We tested for an
association of each variant with T2DM Caucasians (192 cases and 192 controls) and African
Americans (341 cases and 186 controls).
Results: We identified 8 variants in the two populations, including a 3 bp insertion in exon 2
(InsCCG243) in African Americans that resulted in an in-frame proline insertion in the
transactivation domain. No variant was associated with T2DM in Caucasians, but polymorphisms
at -3766 in the human β-cell enhancer, at -2877 bp in the PH1 domain, and at -108 bp in the
promoter region were associated with T2DM in African American subjects (p < 0.01), both
individually and as haplotypes (p = 0.01 correcting by permutation test). No SNP altered a binding
site for the expected β-cell transcription factors. The rare alleles of InsCCG243 in exon 2 showed
a trend to over-representation among African American diabetic subjects (p < 0.1), but this trend
was not significant on permutation test.
Conculsion: The common alleles of regulatory variants in the 5' enhancer and promoter regions
of the IPF1 gene increase susceptibility to type 2 diabetes among African American individuals, likely
as a result of gene-gene or gene-environment interactions. In contrast, IPF1 is not a cause of type
2 diabetes in Caucasians. A previously described InsCCG243 variant may contribute to diabetes
susceptibility in African American individuals, but is of low penetrance.
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Background
Type 2 diabetes (T2DM) has a substantial genetic compo-
nent, but genetic heterogeneity, gene-environment inter-
actions, and a large number of loci with small effect have
combined to confound the identification of susceptibility
genes. The pathogenesis of T2DM is characterized by early
resistance to insulin-mediated glucose uptake and β-cell
dysfunction followed by the further inexorable decline in
function and possibly mass [1]. To maintain insulin secre-
tion and glucose homeostasis in the face of resistance to
insulin mediated glucose uptake, the β-cell must increase
insulin secretion, either by increased function or increased
β-cell mass, a concept known as β-cell compensation [2].
Impaired β-cell function predicts future diabetes [3], and
work from our laboratory [4] and others [5,6] suggest that
the ability of the pancreatic β-cell to compensate for pre-
vailing insulin sensitivity (ie, β-cell compensation) is
highly heritable. Nonetheless, the genetic controls over β-
cell failure are largely unknown.
The islet transcription factor, insulin promoter factor 1
(IPF1) gene (also known as the pancreatic duodenal
homeobox 1, PDX1, and insulin upstream factor 1, IUF1),
is required for both the differentiation and maintenance
of the β-cell phenotype [7]. The importance of IPF1 in
pancreatic  β-cell development and function is demon-
strated in naturally occurring human mutations and in
experimental mouse models. Humans lacking a func-
tional IPF1 allele have pancreatic agenesis [8], whereas
humans heterozygous for the same variant develop early
onset, insulin deficient diabetes (Maturity Onset Diabetes
of the Young, MODY4) [9]. Similarly, mice homozygous
for targeted disruption of IPF1 (PDX1) fail to develop a
pancreas, whereas haploinsufficient mice have impaired
glucose-stimulated insulin secretion and develop T2DM
with aging [7]. Impaired glucose homeostasis with
reduced IPF1 activity likely derives from an influence on
both β-cell mass and function. Both isolated mouse islets
and dispersed β-cells with haploinsufficiency for IPF1
showed increased apoptosis even at basal glucose levels,
but were functionally normal [10]. However, IPF1 also
transactivates the promoters of multiple islet-specific
genes, including insulin, the GLUT2 islet glucose trans-
porter, islet amyloid polypeptide (IAPP), and somatosta-
tin [11]. Thus, IPF1 sequence variants might be expected
to influence both β-cell mass and the expression of key β-
cell genes.
Regulation of IPF1 gene expression is complex, with mul-
tiple upstream regulatory elements that bind other key β-
cell genes including HNF3β, HNF1α, and SP transcription
factors [12,13]. Upstream sequences include a human and
β-cell specific enhancer region at -3.7 kb to -3.4 kb that
binds HNF1α, HNF3β, SP1, and SP3, and 3 additional
regions that are highly conserved between mouse and
human: PH1 (-2.6 kb to -2.8 kb), PH2 (-2.1 kb to -2.2 kb),
and PH3 (-1.6 kb to -1.9 kb) [14]. PH1 and PH2 bind
HNF3β, and PH1 also binds IPF1 [12] and HNF1α [15].
Multiple studies have examined the IPF1 gene for muta-
tions in early onset, autosomal dominant diabetes and a
few studies have searched for mutations in T2DM in Cau-
casians [16-19]. Only rare coding variants have been iden-
tified. However, neither the far upstream regulatory
regions nor other ethnic groups including African Ameri-
cans have been examined. We hypothesized that common
variants in coding or regulatory regions of the IPF1 gene
contribute to the failure of β-cell compensation and to the
susceptibility to common T2DM. To address this hypoth-
esis, we screened the coding and upstream regulatory
regions of the IPF1 gene in both African American and
Caucasian diabetic individuals with a family history of
diabetes. We then tested both individual variants and
haplotypes for diabetes susceptibility using a case-control
design for each population.
Methods
Experimental subjects
We examined two populations: Caucasian individuals
ascertained primarily for Northern European Ancestry,
and African American individuals. Screening for new
sequence variants was conducted in two stages. Initial
studies of coding, 5' and 3' untranslated regions, 5' flank-
ing region, and far upstream enhancer and regulatory ele-
ments upstream were conducted in 48 individuals: 12
African American subjects with T2DM, 12 African Ameri-
can control subjects, 12 Caucasian subjects with T2DM,
and 12 nondiabetic Caucasian subjects. To better detect
uncommon coding variants, we subsequently screened an
additional 45 African American subjects with T2DM and
an additional 47 Caucasian subjects with T2DM for
exonic regions. Thus, exons were screened in total for 12
African American control subjects and 57 African Ameri-
can subjects with T2DM, and for 12 Caucasian control
subjects and 59 Caucasian subjects with T2DM. To further
improve sensitivity to detect coding variants, we selected
affected subjects with early onset of T2DM: ages 25 – 40
years in African American subjects, and ages 30 – 45 years
in Caucasian subjects.
Case control studies were conducted similarly in both
Caucasian and African American populations. Our Cauca-
sian study comprised 188 unrelated nondiabetic control
individuals (73 male, 115 female) and 190 individuals
with T2DM (133 male, 57 female), and has been
described previously [20]. This population has 80%
power to detect an absolute difference in allele frequen-
cies of 10% difference between cases and controls for
minor allele frequencies in controls of 10% to 50%. Initial
case-control studies in African Americans were conductedBMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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on 165 control individuals (82 male, 83 female) and 255
diabetic cases (142 male, 113 female). This population
likewise has at least 80% power to detect a difference
between case and control allele frequencies of 10% over
the range of allele frequencies from 10% to 50%. For both
case-control studies, all diabetic individuals had at least
one diabetic first degree relative. Control individuals had
a normal 75 g oral glucose tolerance test or a fasting or
random glucose below 5.6 mmol/l, and no diabetic first
degree relative. No individual with known impaired glu-
cose tolerance was included in either group, but because
some subjects were ascertained at health fairs, not all sub-
jects underwent glucose tolerance testing and thus
impaired glucose tolerance could not be excluded.
During the course of this study, additional African Ameri-
can samples became available. Given the evidence for
association and newly available samples, we subsequently
expanded typing for SNPs 1, 4, 11, and the INSCCG243
variant by an additional 21 African American cases and 85
African American controls. Hence, for these markers we
present data for on 186 African American controls (95
male, 91 female) and 341 African American diabetic indi-
viduals (186 male, 155 female). The African American
control population had a BMI of 30.2 ± 7.1 kg/m2 and an
age of 42.7 ± 13.0 years. The African American T2DM pop-
ulation had a BMI of 32.4 ± 7.3 kg/m2, and age of diabetes
diagnosis of 42.6 ± 11.9 years, and an age at testing of 55.0
± 12.6 years. All subjects provided informed consent
under protocols approved by the University of Utah or
University of Arkansas for Medical Sciences Institutional
Review Boards.
Mutation detection and genotyping
We designed primers from the human genome sequence
(AL353195) and alignment with the human IPF1 mRNA
sequence (NM_000209) to cover exons 1 and 2, the 5' and
3' untranslated regions, 1.5 kb of 5' flanking and proximal
promoter sequence, and the reported enhancer and regu-
latory elements PH1, PH2, and PH3 at positions -3.6 kb,
-2.76 kb, -2.2 kb, and -1.76 kb from the ATG start site
[12,15] (Figure 1). Initial screening was by denaturing
high pressure liquid chromatography (DHPLC) using a
Transgenomic WAVE HT DNA Fragment Analysis System
(Transgenomic, Inc, Omaha, NE). Altered migration was
confirmed and characterized by bidirectional sequence
analysis [21] using infrared dye-labeled primers and
GR4200 Sequencers (LI-COR Biotech, Lincoln, NE).
The proline insertion variant (InsCCG243) was typed
using infrared dyes with detection on a LICOR GR4200
sequencer and scored using SAGA GT fragment analysis
software (LICOR Biotech). Because the sequences in the
exon 2 around the InsCCG243 variant are highly G-C rich,
we confirmed our results using the Advantage GC-2 PCR
kit (BD Biosciences Clontech, Palo Alto, CA). The remain-
ing 8 SNPs were genotyped by Pyrosequencing on a PSQ-
96 machine according to manufacturer methods (Biotage
AB, Uppsula, Sweden). Primer sequences are available in
Table 1.
Statistical and binding factor analyses
Our primary analysis was allelic association. Allelic fre-
quencies in cases and controls were compared using the
Fisher exact test. We report both the uncorrected p values
Map of the IFP1 gene and upstream regulatory regions Figure 1
Map of the IFP1 gene and upstream regulatory regions. Upstream regulatory regions are shown in white boxes. Exons are 
shown in boxes; translated regions are black and the untranslated regions are grey. The approximate locations of each SNP and 
the CCG (proline) insertion polymorphism are shown. Lines with arrow heads show the areas covered for PCR/DHPLC 
screening.BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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for allelic association and the simulated p values which
correct for the number of tests using HaploView version
3.2 [22]. We considered p < 0.05 to be significant without
correction for multiple testing. In exploratory analyses, we
also examined SNPs with an allelic association of p < 0.10
using several analyses. First, we tested for a genotypic asso-
ciation using the Fisher Exact Test under dominant and
recessive models. Second, we tested for association using
logistic regression analysis under additive, dominant and
recessive models. For uncommon SNPs in which few
recessive individuals were observed, recessive and additive
models were not tested. Logistic regression included age
(testing age for controls, age of diagnosis for cases), ln-
transformed body mass index (BMI), and gender as
covariates.
Pair-wise linkage disequilibrium coefficients were calcu-
lated by allele counting from the combined case and con-
trol data. Phase was estimated using the Expectation
Maximum algorithm. Haplotype distribution between
cases and controls was tested using Phase v2.1.1 [23],
Arlequin [24], or HaploView v3.2 [22]. TagSNPs were
selected using the LDSelect program based on the correla-
tion between SNPs (r2) set at 0.8 [25]. Altered transcrip-
tion factor binding sites were identified using the
TFSEARCH program based on the TRANSFAC database
[26].
Results
We detected a total of 9 sequence variants, including 8
SNPs in noncoding regions and a single coding variant
observed only in African American subjects and compris-
ing a 3 bp CCG/proline insertion (InsCCG243) in exon 2
(Table 2 and Figure 1). No other common or rare coding
variants were detected among a total of 138 African Amer-
ican or 142 Caucasian alleles, including the previously
reported D76N variant [17,19]. We identified 3 SNPs in
the far 5' regulatory sequences, including one SNP in the
human-specific enhancer region (SNP1) and two SNPs
(SNP3, SNP4) in the PH1 region. SNP3 was common
among Caucasians but not observed in African Americans.
Two additional SNPs (SNP2, SNP11) were located in the
proximal 5' flanking region (Figure 1).
We tested each of 7 SNPs that had minor allele frequen-
cies over 10% in 190 Caucasian individuals with T2DM
and 188 Caucasian control individuals. No individual
SNP was associated with T2DM (p > 0.9 on permutation
p value for all; Table 2 shows allelic frequencies, Table 3
provides raw numbers). The complete variation in the 7
SNPs could be captured with only 4 tagSNPs (SNPs 1, 2,
3, and 4 at positions -3766, -2890, -2877, and -279). All 7
SNPs fell into a single haplotype block with pairwise D'
values of 1.0. Consistent with these observation, only 4
haplotypes were observed at over 1% frequency (Table 4).
The 4 haplotypes could be distinguished by typing SNP 2,
SNP 3, and SNP 4. Neither the distribution of haplotypes
in Caucasians (p = 0.98 by Phase v2.1.1), nor any individ-
ual haplotype (p > 0.44; Table 4) was associated with
T2DM.
In contrast to Caucasians, SNP1 in the human β-cell spe-
cific enhancer, SNP4 in the PH1 region, and SNP11, a G
insertion in the proximal 5' flanking region, were signifi-
cantly associated with T2DM (p = 0.007, p = 0.008, and p
= 0.0008, respectively), with predicted odds ratios for the
major allele of 1.59, 1.45, and 1.79, respectively. In con-
trast, the proline insertion in exon 2 (InsCCG243)
showed a trend to an association, but did not reach statis-
tical significance even without correction for multiple test-
ing (p = 0.088, OR 1.58). The common alleles of SNPs 1,
4, and 11 were over-represented in subjects with T2DM,
whereas the insertion allele of InsCCG243 was increased
in T2DM subjects. SNPs 1 and 11 were in strong linkage
disequilibrium (r2 = 0.927). Based on r2>0.8, we could
capture the full diversity among African American subjects
Table 1: Primer sequences for IPF1 SNPs
SNP NAME FORWARD PRIMER 5' to 3' REVERSE PRIMER 5' to 3' SEQUENCE PRIMER 5' to 3' Anneal 
Temp.
SNP1 *ATTGCTTAGCCCTAGGAATAT AGAGGGGCCAGGGAAACCCAG GGATTGGAGAGAGGAAA 55°C
SNP2 GACGCCAGCTGCCCGTTCA *CTGGCTGGCCGCACTAAGAG AATTGGAACAAAAGCAG 55°C
SNP3 rs2293942 GGCAAGGACCTCCAGTATCAG *CCCGAGCCATTTAACAG CCTCCAGTATCAGCGAGGAC 55°C
SNP4 rs2293943 *GGCAAGGACCTCCAGTATCAG CCCGAGCCATTTAACAG TGAAAAAGTCGTTTATTAGC 55°C
SNP5 rs4002827 GATATCATGGAAAATGCAGCG *GCTTCCCAATACAGCGAGG GCAGAAGAGAGTGAGTGTT 55°C
SNP6 GTTTCGAGAAACGTCCTCATTT *GCTTCTGGGGTCCTGACT CAGTCAGAGGCTGGTCA 55°C
SNP8 rs4430606 Acttcccgcgcttcgtta *CCAGCCCCTTCCTCTTTACT CCAGGTAGGTGCAGAAAG 52°C
SNP11 GTCGTGCGGAGCTGTCAAAGCGAG *CTGGAGCCGGGGATTT AGCTGTCAAAGCGAGCAGGG 55°C
InsCCG243 CACGACGTTGTAAAACGACGAGACA
CATCAAGATCTGGTTCCAA
GGATAACAATTTCACACAGGGC
AGCGGGCGGCACA
* Denotes additional of universal primer sequence to the primer. Universal primer sequence is as follows: TCTGCTGCTCCGGTTCATAGATT-3'BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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with 6 tagSNPs: SNPs 1, 2, 4, 5, 6, and InsCCG243. Using
all observed variants, we identified only 7 haplotypes with
over 1% frequency. Only Ins243CCG fell outside of the
block defined using confidence interval definitions (Fig-
ure 2). Although the overall distribution of haplotypes
was different between cases and controls (permuted p =
0.01), no single haplotype was over-represented in cases
compared with controls (Table 5). In contrast, when the 3
individually associated variants were examined together,
2/3 haplotypes showed 8% differences between cases and
controls (Table 5). The Ins243CCG proline insertion split
the most common haplotype, and occurred on a single
haplotype that showed a similar distribution between
cases and controls as the Ins243CCG SNP (Table 5).
When Ins243CCG was included in the analysis, neither
major haplotype (CAID or CAII, where I is the insertion of
the G at SNP 11 or the proline at Ins243CCG and D is the
absence of the extra bases) was associated with T2DM
when the proline insertion was included, but was associ-
Table 2: IFP1 Variation and Association with Type 2 Diabetes
Name Variat dbSNP Posit Popul Frequency, Caucasian Frequency, Af. American
Cases Controls Cases Controls
SNP1 C/T ------ -3766 AA/Cauc 0.183 (0.143, 0.223) 0.192 (0.152, 0.232) 0.144 (0.118,0.170) 0.2101 (0.167,0.253)
SNP3 T/C rs2293942 -2890 Cauc 0.278 (0.232, 0.324) 0.249 (0.206, 0.292) ------ ------
SNP4 A/T rs2293943 -2877 AA/Cauc 0.339 (0.291, 0.387) 0.369 (0.321,0.417) 0.289 (0.255,0.323) 0.3702 (0.321,0.419)
SNP6 G/T ------ -1263 AA/Cauc 0.196 (0.156, 0.236) 0.189 (0.151, 0.229) 0.119 (0.091,0.147) 0.129 (0.093, 0.165)
SNP5 C/T rs4002827 -992 AA ------ ------ 0.071 (0.048, 0.094) 0.044 (0.021, 0.067)
SNP2 G/A ------ -279 AA/Cauc 0.458 (0.408, 0.508) 0.429 0.379, 0.479) 0.114 (0.086, 0.142) 0.139 (0.101, 0.177)
SNP11 (G)4/(G)3 ------ -108 AA/Cauc 0.182 (0.143, 0.221) 0.177 (0.138, 0.216) 0.134 (0.108, 0.160) 0.2173 (0.175, 0.259)
SNP8 G/T rs4430606 +918 AA/Cauc 0.197 (0.157, 0.237) 0.191 (0.152, 0.232) 0.115 (0.087, 0.143) 0.133 (0.096, 0.170)
InsCCG243 InsCCG ------ +4437 AA ----- ----- 0.091 (0.069, 0.113) 0.0604 (0.035, 0.085)
Name, name from Figure 1 and text; variant, major/minor allele except for InsCCG243, in which the insertion is the minor allele; dbSNP, catalog 
number in public database if available; position, location relative to ATG start; Populat, population in which variant was detected, AA is African 
American, Cauc is Caucasian; frequency, minor allele frequency. Frequencies are shown with 95% confidence intervals in parentheses. Significance by 
Fisher Exact test: 1p = 0.007;2p = 0.008; 3p = 0.0008; 4p = 0.088; simulated p values based on 10,000 replicates were 0.027, 0.029, 0.002, and 0.28, 
for SNP1, SNP4, SNP11, and InsCCG243, respectively. No other simulated p values approached significance.
Table 3: Raw Counts for Caucasian and African American Case Control Studies
SNP 
Name
Caucasian African American
Major/Major Major/Minor Minor/Minor Major/Major Major/Minor Minor/Minor
DM Cnt DM CNT DM CNT DM CNT DM CNT DM CNT
SNP 1 120 124 54 59 6 7 249 117 84 60 7 9
SNP 2 54 61 97 95 38 34 197 124 53 35 2 3
SNP 3 97 73 15 108 71 12 --- --- --- --- --- ---
SNP 4 84 82 43 76 89 26 169 147 25 79 75 31
SNP 5 --- --- --- --- --- --- 210 143 34 14 1 0
SNP 6 124 125 56 58 7 9 200 119 53 43 2 3
SNP 8 123 123 56 58 9 7 198 115 50 41 2 3
SNP 11 125 8 51 125 53 6 253 114 76 57 7 11
ProIns --- --- --- --- --- --- 265 57 1 155 21 0
Numbers of individuals with each genotype are shown for the SNPs in Table 1. Significance by allelic association is shown in Table 1 with confidence 
intervals for allele frequencies. Note that allelic association was the primary test performed. Data not shown (--) was not typed in the full case 
control set because of low frequency. Counts differ slightly due to genotypes that were not called, and because additional African American samples 
were typed for SNPs 1, 4, 11, and ProIns (proline insertion) based on initial data showing an association.BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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ated when not split. Hence, the proline insertion was not
driving the observed association.
In exploratory analyses, we sought to determine the most
likely mode of inheritance and to determine whether the
observed allelic associations were modulated by age, age
of onset, or obesity. SNPs 1 and 11 acted as a recessive trait
for the major allele (p = 0.017 and 0.003, respectively),
whereas SNP 4 acted as a dominant trait for the major
allele (p = 0.0016). No other SNP was associated with
T2DM on exploratory analyses. Logistic regression con-
firmed the allelic association tests. Only SNPs 1, 4, and 11
and BMI were significant factors in the model. SNP 4
showed a stronger dominant effect (p = 0.0002, OR 3.23)
with correction for age, BMI, and gender, whereas SNPs 1
and 11 were again consistent with a recessive effect of the
major allele (p = 0.017 and 0.003, respectively, and OR
1.713 and 1.916, respectively).
The haplotype analysis and association analyses did not
suggest which of the 3 SNPs was driving the observed
association. No SNP altered the binding sites for known β-
cell regulatory factors, including HNF1α, HNF1β, HNF3β,
SP1/3, or auto-regulatory IPF1/PDX1 binding [13]. How-
ever, the minor allele of SNP1 abolished the predicted
binding of heat shock factors 1 and 2 (HSF1 and HSF2),
which are involved in cellular stress responses [27].
Discussion
As a key transcription factor in the pathways controlling
both β-cell mass and essential genes for insulin biosynthe-
sis and secretion, IPF1 is a strong candidate for the inher-
ited defect in insulin secretion that characterizes T2DM
and the prediabetic state. Mutations in IPF1 are a rare
cause of early onset T2DM (MODY4)[16,18,28]. Several
previous studies have searched for mutations in late onset
T2DM among Caucasians [17,19,28] with variable results,
but these studies have not focused on the well described
conserved elements that extend 5 kb upstream of the ATG
translation start site. Furthermore, no published study has
examined a non-Caucasian population. The role of previ-
ously reported, rare nonsynonymous SNPs in typical
T2DM [17,19] is unclear. We recently were unable to dem-
onstrate a major role in T2DM susceptibility or in reduced
insulin secretion for the most common of these missense
variants, D76N, among Caucasians [29]. In screening 282
African American diabetic and 96 African American con-
trol subjects, we observed the D76N variant only in 3 indi-
viduals with T2DM (allelic frequency 0.005), and thus
lacked the power to evaluate this variant in African Amer-
ican subjects. In the present study, we found no new cod-
ing variants among Caucasian samples, nor were any of 6
SNPs in the 5' flanking region, including those in the
enhancer and PH1 domains, associated with T2DM in
Caucasians. The lack of involvement of IPF1 in Cauca-
sians was supported by the haplotype analysis.
In contrast, 3 of 8 sequence variants in African Americans
were associated with T2DM, and two variants that were
not seen in Caucasians showed a trend to an association.
SNPs 1 and 11 (G insertion at -108 bp) were in strong
linkage disequilibrium. SNP11 was previously reported in
Japanese, where the (G)4 allele was less common than in
African Americans and was of similar frequency in 88
cases and 67 controls [30]. Genetic studies likely cannot
distinguish the impact of SNP1 in the enhancer and
Table 4: Haplotypes observed in the Caucasian Population
Haplotype Case Freq Control Freq p value
CTAGGIG 0.337 0.364 0.4406
CCTGAIG 0.269 0.247 0.4939
TTTTGDT 0.192 0.187 0.8625
CTTGAIG 0.184 0.186 0.936
Haplotypes observed at over 1% frequency are shown for SNPs 
observed in the Caucasian population (SNPs 1, 3, 4, 6, 2, 11, and 8). 
SNP 11 is shown as I (insertion, G4 or 4 G's) or D (deletion, G3 or 3 
G's). All other SNPs are shown as listed in Table 2.
Linkage disequilibrium (D') plot of the IPF1 gene in African  American subjects Figure 2
Linkage disequilibrium (D') plot of the IPF1 gene in African 
American subjects. SNPs are shown by location as in Table 1 
and Figure 1. Squares without numbers represent D' values 
of 1.0; all numbers represent the D' value expressed as a per-
centile. Red squares represent pairs with LOD score for link-
age disequilibrium of ≥ 2, blue squares represent D' = 1 but 
LOD<2, and white squares represent LOD<2 and D'<1.0. 
Plots were generated using HaploView v3.2.BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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SNP11 in the proximal promoter on IPF1 transcription.
The association of SNP11 was statistically the strongest.
The haplotypes constructed from SNPs 1, 4, and 11
together confirmed the individual SNP results, but the
association was not stronger using either PHASE or Hap-
loView 3.2 than observed for individual SNPs. Hence, we
cannot determine whether SNPs 1, 4, and 11 might inter-
act to increase the risk of T2DM. Examination of the two
haplotypes that were associated with T2DM showed that
the risk and protective haplotypes differed at all three
positions (CAG4 vs TTG3). Only the G3 allele uniquely dis-
tinguished a haplotype that differed in frequency between
cases and controls. Notably, this haplotype is protective
with regard to T2DM susceptibility. The "risk" haplotype
(GAG4) is very common (71% of T2DM, 62.5% of
controls). The contribution of the high prevalence allele
to T2DM susceptibility has also been seen in other T2DM
susceptibility genes, such as the PPARγ Pro12Ala variant
[31].
The SNPs detected in this study are not predicted to alter
the binding of known regulators of IPF1 gene expression,
including HNF1α, HNF3β, or IFP1/PDX1, which have
been shown to bind to these two regions [14]. SNPs 3 and
4 lie only 33 bp apart in the highly conserved PH1 ele-
ment and approximately 50 bp upstream of the binding
sites for known β-cell transcription factors NKX2.2, PBX1,
and HNF3β. Several predicted binding sites for other tran-
scription factors are altered by these associated variants.
As noted above, the minor (T) allele of SNP1 is predicted
to abolish the binding of heat shock proteins HSF1 and
HSF2, although the role in insulin secretion or β-cell
function is speculative. The common (A), T2DM-associ-
ated allele of SNP4 was predicted to abolish binding of
the transcription factor Ets1. Ets1 has been described pri-
marily in oncogenesis and angiogenesis, and is expressed
in endothelial and lymphoid cells [32]. A role in the
pancreatic β-cell has not been described previously. For
SNP11, the T2DM-associated (G)4 was predicted to bind
basic helix-loop-helix factor E47, whereas this binding
was not present for the minor (G)3 allele. E47 is widely
distributed, including pancreatic β-cells where it is well
described as a regulator of insulin gene transcription [33].
Binding of E47 to the (G)4 allele might block activation by
other transcription factors, and thus explain the
association.
SNPs 1, 4, and 11 were not associated with T2DM in Cau-
casians. Thus, the association in African Americans may
result from gene-gene or gene-environment interactions
that are unique to this population. Alternatively, African
Americans are known to be an admixed population, and
concerns have been raised regarding spurious associations
as a result of this admixture [34,35]. Several factors argue
against a spurious association based on population struc-
ture, however. First, the 3 associated SNPs have similar
frequencies in Caucasians and African Americans, such
that population structure from admixutre would be less
likely to lead to a spurious association. Second, of 87
SNPs previously typed, including 16 randomly chosen for
Table 5: Haplotypes for 8, 4, and 3 Markers Observed in the African American Population
Variants No Haplotype Case Freq Control Freq ChiSq P value Simulated p 
value
Global p
1,4,6,5,2,11,8,P
1 CAGCGIGD 0.531 0.511 0.326 0.5683 1 0.01
2 TTTCGDTD 0.103 0.145 3.336 0.0678 0.465
3 CTGCAIGD 0.112 0.124 0.247 0.6193 1
4 CAGCGIGI 0.108 0.064 4.676 0.0306 0.239
5 CAGTGIGD 0.072 0.046 2.389 0.1222 0.693
6 TTGCGDGD 0.031 0.067 5.873 0.0154 0.131
7 CTGCGIGD 0.026 0.024 0.014 0.9057 1
1,4,11,P
1 CAID 0.622 0.565 3.197 0.0738 0.3053 0.01
2 TTDD 0.138 0.209 9.084 0.0026 0.0094
3 CTID 0.143 0.151 0.134 0.714 0.9995
4 CAII 0.088 0.059 2.735 0.098 0.3809
1,4,11
1 CAI 0.71 0.625 7.96 0.0048 0.02 0.01
2 TTD 0.138 0.209 9.085 0.0026 0.011
3 CTI 0.145 0.152 0.091 0.763 1
Haplotypes observed at over 1% frequency for all 8 variants, the 4 variants typed in additional individuals, and the three variants that showed an 
association with T2DM. Simulated p values are based on 10,000 simulations in HaploView 3.2; global p values are based on simulations conducted in 
Phase 2.1.1.BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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large differences in African American and Caucasian allele
frequencies and 71 chosen from candidate genes, only 3
have shown differences in allele frequencies that were sig-
nificant at the p < 0.05 level. Thus, the findings in the cur-
rent study have not been observed for multiple other
genes tested.
Recently, lack of power has been raised as a reason for the
inconsistent replication of associations [31,36,37], and
very large sample sizes have been proposed to detect the
small effects of variants such as the P12A polymorphism
of the PPARγ gene or the E23K variant of the β-cell potas-
sium channel, KCNJ11 [38]. By these standards, our study
is small and likely would not have detected effects in
either Caucasian or African American populations with a
relative risk of below 1.4. However, among Caucasians we
found no trend to an association. Indeed, for SNP 3,
which showed the largest difference between cases and
controls for any IPF1 SNP in Caucasians, achievement of
80% power to detect a difference significant at p < 0.05
would require 1700 cases and 1700 controls, based on a
test of allelic association (3400 alleles for each group).
Thus, although we cannot exclude an effect of these vari-
ants on T2DM risk that is comparable to that of PPARγ,
the likelihood that a large enough study will be performed
is small. The tagSNPs derived from our study will be use-
ful should other investigators choose to undertake such a
study.
The most intriguing of the unique African American vari-
ants is InsCCG243, which results in the inframe insertion
of a proline in the carboxy-terminal polyproline tail, a
region that is predicted to be involved in transactivation.
We found this variant exclusively among African Ameri-
can subjects. We did not observe InsCCG243 among 142
Caucasian haplotypes, nor have other authors reported
this variant in Caucasian populations [19,28].
InsCCG243 was reported previously in two French fami-
lies, where it appeared to segregate in an autosomal dom-
inant fashion and was associated with progressive insulin
impairment [17]. The ethnic origin of these French fami-
lies was not reported [17] and may have been of African
or Afro-Caribbean. Expression of the InsCCG243 allele
inhibited the endogenous IPF1 activation of the insulin
gene by over 50% [17]. In the current study, InsCCG243
had an allele frequency of nearly 10% among diabetic
subjects and 6.3% among controls. However, this differ-
ence did not reach statistical significance under any model
in our studies. Hence, although InsCCG243 could con-
tribute to 18% of T2DM among African Americans, the
high prevalence observed in control individuals who had
normal glucose tolerance and no family history of T2DM
is inconsistent with the very high penetrance suggested by
Linkage disequilibrium (D') plot of IPF1 gene in Caucasians Figure 3
Linkage disequilibrium (D') plot of IPF1 gene in Caucasians. 
SNPs are shown by location as in Table 1 and Figure 1. As in 
Figure 2, plots were generated in HaploView v3.2. Squares 
without numbers represent D' values of 1.0; all numbers rep-
resent the D' value expressed as a percentile. Red squares 
represent pairs with LOD score for linkage disequilibrium of 
≥ 2, blue squares represent D' = 1 but LOD<2, and white 
squares represent LOD<2 and D'<1.0. plots were generated 
using HaploView v3.2.
Linkage disequilibrium (r2) plot for in African Americans Figure 4
Linkage disequilibrium (r2) plot for in African Americans. Fig-
ure 4 is analogous to the D' plots shown in Figure 2. The r2 
value is shown on a grey scale, where white represents r2 = 
0, black represents r2 = 1, and shades of grey represent 
0<r2<1. All plots were generated using HaploView v3.2. SNP 
names and locations are as in Figure 2.BMC Medical Genetics 2005, 6:37 http://www.biomedcentral.com/1471-2350/6/37
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Hani et al [17]. Furthermore, among our African Ameri-
can families, InsCCG243 did not segregate in an auto-
somal dominant fashion (unpublished observations).
Conclusion
We have carefully examined the IPF1 gene in two ethnic
groups. We have extended earlier studies to the highly
conserved upstream regulatory regions. Although we find
no evidence for an association with T2DM among Cauca-
sians, three putative regulatory variants are associated
with T2DM in African Americans. Furthermore, a proline
insertion in the transactivation domain was unique to
African Americans and showed a trend to an association.
These variants thus may explain part of the increased dia-
betes prevalence among African Americans. However, the
lack of association of the same variants in Caucasians sug-
gests gene-gene or gene-environment interactions, or per-
haps a spurious association due to population structure.
Additional population association and physiologic stud-
ies will be needed to confirm and extend these findings.
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